How to Commercialize a Therapeutic
Therapeutics require long timelines and substantial capital, which makes early sequencing unusually important. The objective is not to eliminate risk before financing—it is to identify which risks must be reduced before the next source of capital or strategic partner will engage.
1. Start with the Target Product Profile
Define the initial indication, patient population, route, dosing concept, competitive standard, target efficacy, safety expectations, and differentiation. A platform may support many programs, but the first asset needs a specific product thesis.
2. Build Translational Evidence around a Partner’s Questions
Mechanistic novelty is not the same as development readiness. Strengthen the connection among target biology, disease relevance, pharmacology, biomarkers, exposure, efficacy, and safety. The exact evidence package depends on modality and indication.
3. Protect the Asset and Understand License Economics
Evaluate composition, use, method, platform, manufacturing, and other IP opportunities as appropriate. For university spinouts, license terms can materially affect future diligence, financing, sublicensing, and acquisition economics.
4. Bring CMC Forward
Chemistry, manufacturing, and controls can become a critical path surprisingly early. Develop a realistic plan for reproducibility, characterization, formulation, stability, scale-up, release testing, and supply appropriate to the stage.
5. Use Regulatory Strategy to Shape Development
FDA interactions such as pre-IND meetings can help sponsors discuss development questions before an IND. The best regulatory strategy is not a document prepared at the end; it is a set of assumptions that guide what work is performed, when, and to what standard.
6. Decide What to Build versus Partner
Some founders should build through IND or early clinical proof of concept. Others may maximize value by partnering earlier. The right point depends on capital needs, competitive timing, internal capabilities, partner appetite, and the evidence required to command acceptable terms.
7. Finance Inflection Points
Use grants, disease foundations, translational programs, strategic research support, and equity in combinations that fit the asset. Major capital should be tied to meaningful events such as candidate selection, IND-enabling completion, IND clearance, first-in-human data, or clinical proof of concept.
BYB Takeaway
Therapeutic commercialization is a sequence of risk-reduction decisions. The strongest teams know which question must be answered next, what evidence will answer it, and which source of capital should pay for that evidence.
Do not build the entire company plan around the science alone; build it around the next value inflection point.
Source notes
FDA, IND Meetings for Human Drugs and Biologics (guidance): https://www.fda.gov/media/70827/download
